A5054391751- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Peripheral Neuropathies and Disorders
- Radiopharmaceutical Chemistry and Applications
- Hereditary Neurological Disorders
- Sports Performance and Training
- Myasthenia Gravis and Thymoma
- Peripheral Nerve Disorders
- Pancreatic and Hepatic Oncology Research
- Medical Imaging Techniques and Applications
- Motor Control and Adaptation
- Sports injuries and prevention
- Genetic Neurodegenerative Diseases
- Prostate Cancer Treatment and Research
- Mitochondrial Function and Pathology
- Peptidase Inhibition and Analysis
- Primate Behavior and Ecology
- Cardiovascular and exercise physiology
- Balance, Gait, and Falls Prevention
- Winter Sports Injuries and Performance
- Neurological and metabolic disorders
- Neurogenetic and Muscular Disorders Research
- Physical Activity and Health
- Radiomics and Machine Learning in Medical Imaging
University Hospital of Basel
2016-2025
University of Basel
2013-2025
Hôpital Raymond-Poincaré
2013-2024
Université Rennes 2
2014-2024
Institut national de recherche en informatique et en automatique
2019-2024
Université de Versailles Saint-Quentin-en-Yvelines
2013-2024
Inria Rennes - Bretagne Atlantique Research Centre
2019-2024
Université de Rennes
2009-2023
Université Paris-Saclay
2021-2023
Inserm
2004-2023
<h3>Background</h3> Serial electrophysiology has been suggested as essential for accurate diagnosis in Guillain–Barré syndrome (GBS). However, whether more adapted electrophysiological criteria may allow a single study to be sufficient is unknown. <h3>Methods</h3> We retrospectively reviewed records of 365 consecutive patients with GBS from Birmingham, UK, and Garches, France, admitted between 1998 2013. Electrophysiology was analysed using existing well set modified criteria, developed...
<h3>Objective:</h3> To determine whether rituximab 375 mg/m<sup>2</sup> was efficacious in patients with immunoglobulin M (IgM) anti-myelin–associated glycoprotein antibody demyelinating neuropathy (IgM anti-MAG neuropathy). <h3>Methods:</h3> Fifty-four IgM were enrolled this randomized, double-blind, placebo-controlled trial. The inclusion criteria inflammatory cause and treatment (INCAT) sensory score (ISS) ≥4 visual analog pain scale >4 or ataxia ≥2. primary outcome mean change ISS at...
BackgroundSmall benign insulinomas are hard to localise, leading difficulties in planning of surgical interventions. We aimed prospectively assess the insulinoma detection rate single-photon emission CT combination with (SPECT/CT) a glucagon-like peptide-1 receptor avid radiotracer, and compare rates conventional CT/MRI techniques.MethodsIn our prospective imaging study, we enrolled adults aged 25–81 years at centres Germany, Switzerland, UK. Eligible patients had proven clinical biochemical...
Objective To compare the natural history of familial transthyretin amyloid polyneuropathies (FAP) due to Val30Met, Ser77Tyr, and Ile107Val mutations in France with classical Portuguese Val30Met FAP. Methods We compared 84 French patients a control group 110 carrying mutation also living France, all referred followed at National FAP Reference Center from 1988 2010. Clinical examination, functional walking disability scores, nerve conduction studies, muscle biopsies are reported. conducted...
Abstract Objective Mutations of the mitofusin 2 gene (MFN2) may account for at least a third cases Charcot–Marie–Tooth disease type (CMT2). This study investigates mitochondrial cellular bioenergetics in MFN2 ‐related CMT2A. Methods Mitochondrial network morphology and metabolism were studied cultures skin fibroblasts obtained from four CMT2A patients harboring novel missense mutations gene. Results Although appeared morphologically unaltered, there was significant defect coupling associated...
<h3>Background:</h3> Diagnostic criteria for chronic inflammatory demyelinating polyneuropathy (CIDP) have variable sensitivity and specificity. Newly published by Koski <i>et al</i> combine clinical electrophysiological components, either of which suffices to establish the diagnosis. European Federation Neurological Societies/Peripheral Nerve Society (EFNS/PNS) require mandatory electrophysiology, as do other sets criteria. <h3>Methods:</h3> The value two above-mentioned criteria, on 151...
Radiolabeled somatostatin (sst) receptor agonists are integral to the diagnosis of gastroenteropancreatic neuroendocrine tumors (NETs), but detection rates, especially liver metastases, remain limited even with PET/CT. <sup>68</sup>Ga-OPS202 (<sup>68</sup>Ga-NODAGA-JR11; NODAGA = 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid and JR11 Cpa-c(dCys-Aph(Hor)-dAph(Cbm)-Lys-Thr-Cys)-dTyr-NH<sub>2</sub>)), a novel radiolabeled sst antagonist high affinity for sst<sub>2</sub> receptor, has...
Radiolabeled somatostatin receptor (SSTR) antagonists have shown in vivo higher uptake SSTR-expressing tumors than agonists. In this preclinical study, the SSTR2 antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH<sub>2</sub>]) labeled with <sup>177</sup>Lu, <sup>90</sup>Y, and <sup>111</sup>In was compared agonist <sup>177</sup>Lu-DOTATATE. <b>Methods:</b> Biodistribution, pharmacokinetics, SPECT/CT, dosimetry studies were performed to assess...
The prognosis of patients with progressive meningioma after failure surgery and radiotherapy is poor. We retrospectively evaluated the safety efficacy somatostatin-receptor (SSTR)-targeted radionuclide therapy (177Lu-DOTATATE [n = 16], 90Y-DOTATOC 3], or both 1]) in progressive, treatment-refractory meningiomas (5 World Health Organization [WHO] grade I, 7 WHO II, 8 III) part multifocal disease (17 20 patients). SSTR treatment (median 3 cycles, median administered dose/cycle 7400 MBq) led to...
<sup>111</sup>In-DOTA-exendin-4 SPECT/CT has been shown to be highly efficient in the detection of insulinomas. We aimed at determining whether novel PET/CT imaging with [Nle<sup>14</sup>,Lys<sup>40</sup>(Ahx-DOTA-<sup>68</sup>Ga)NH<sub>2</sub>]exendin-4 (<sup>68</sup>Ga-DOTA-exendin-4) is feasible and sensitive detecting benign <b>Methods:</b><sup>68</sup>Ga-DOTA-exendin-4 were performed a randomized cross-over order on 5 patients endogenous hyperinsulinemic hypoglycemia. The gold standard...
Abstract Previous studies have described the clinical, serological and pathological features of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) antibodies directed against paranodal proteins neurofascin-155, contactin-1 (CNTN1), contactin-associated protein-1 (Caspr1), or nodal forms neurofascin. Such are useful for diagnosis potentially treatment selection. However, targeting Caspr1 only Caspr1/CNTN1 complex been reported in few CIDP. Moreover, it is unclear...
Abstract Electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) were proposed by an Ad Hoc Subcommittee of the American Academy Neurology (AAN) in 1991. Only 60% CIDP patients fulfilled these criteria, which therefore appear poorly sensitive. We sought to revise electrophysiological criteria. selected 40 and compared them with 35 axonal polyneuropathy, 116 Charcot‐Marie‐Tooth type 1A (CMT1A) disease, 66 immunoglobulin M (IgM) monoclonal gammopathy....
Bombesin receptors are overexpressed on a variety of human tumors. In particular, the gastrin-releasing peptide receptor (GRPr) has been identified prostate and breast cancers gastrointestinal stromal The current study aims at developing clinically translatable bombesin antagonist–based radioligands for SPECT PET GRPr-positive <b>Methods:</b> A potent antagonist (PEG<sub>4</sub>-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH<sub>2</sub> [AR]) was synthesized; conjugated to chelators DOTA,...
Energy flow has been hypothesized to be one of the most critical biomechanical concepts related tennis performance and overuse injuries. However, relationships among energy during serve, ball velocity, injuries have not assessed.To investigate quality magnitude flow, peaks upper limb joint kinetics compare serve between injured noninjured players.Case-control study; Level evidence, 3.The serves expert players were recorded with an optoelectronic motion capture system. The forces torques...
Preclinical and preliminary clinical evidence indicates that radiolabeled somatostatin (sst) receptor antagonists perform better than agonists in detecting neuroendocrine tumors (NETs). We performed a prospective phase I/II study to evaluate the sst antagonist <sup>68</sup>Ga-OPS202 (<sup>68</sup>Ga-NODAGA-JR11; NODAGA = 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid JR11 Cpa-c(dCys-Aph(Hor)-dAph(Cbm)-Lys-Thr-Cys)-dTyr-NH<sub>2</sub>)) for PET imaging. Here, we report results of I...
Treatment of patients with advanced medullary thyroid carcinoma (MTC) is still a challenge. For more than 2 decades, it has been known that the cholecystokinin receptor promising target for treatment MTC radiolabeled minigastrin analogs. Unfortunately, kidney toxicity precluded their therapeutic application so far. In 6 consecutive patients, we evaluated 3-dimensional dosimetry whether improved analog <sup>177</sup>Lu-DOTA-(d-Glu)<sub>6</sub>-Ala-Tyr-Gly-Trp-Nle-Asp-PheNH<sub>2</sub>...
Fibroblast activation protein α (FAP) plays an important role in tissue remodeling and helps tumor cells invade surrounding tissue. We sought to investigate FAP as a prognostic molecular marker colorectal cancer (CRC) using immunohistochemical transcriptomic data. expression clinicopathologic information were obtained from The Cancer Genome Atlas dataset. association with cellular heterogeneity landscape was explored xCell method. evaluated cohort of 92 CRCs 19 non-tumoral found upregulated...